Cargando…
Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity
The overexpression as well as the critical implication of the proprotein convertase PACE4 in prostate cancer progression has been previously reported and supported the development of peptide inhibitors. The multi-Leu peptide, a PACE4-specific inhibitor, was further generated and its capability to be...
Autores principales: | Couture, Frédéric, Ly, Kévin, Levesque, Christine, Kwiatkowska, Anna, Ait-Mohand, Samia, Desjardins, Roxane, Guérin, Brigitte, Day, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465654/ https://www.ncbi.nlm.nih.gov/pubmed/26114115 http://dx.doi.org/10.1155/2015/824014 |
Ejemplares similares
-
Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug
por: Kwiatkowska, Anna, et al.
Publicado: (2019) -
The Multi-Leu Peptide
Inhibitor Discriminates Between
PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate
Cancer Cells
por: Levesque, Christine, et al.
Publicado: (2012) -
PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation
por: Levesque, Christine, et al.
Publicado: (2015) -
PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered (64)Cu-Radiolabeled Peptide Inhibitor()()
por: Couture, Frédéric, et al.
Publicado: (2014) -
Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer
por: Mekdad, Nawel, et al.
Publicado: (2022)